At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 70 enrolled
Drug / intervention
CUDC-907drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Open-Label, Phase 2 Study to Evaluate the Efficacy and Safety of CUDC-907 in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Including Patients With MYC Alterations
In Brief
A Phase 2 clinical trial evaluating CUDC-907 for Relapsed and/or Refractory Diffuse Large B-cell Lymphoma Including With Myc Alterations. Completed, enrolled 70 participants across 25 sites in 2 countries.
Detailed Summary
This is a Phase 2, open-label, multicenter trial designed to evaluate the efficacy and safety of CUDC-907 in subjects 18 years and older with Relapsed/Refractory (RR) MYC-altered Diffuse Large B-Cell Lymphoma (DLBCL).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesSpain, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedFeb 2016
Enrollment StartJul 2016
Primary CompletionMay 2019
TodayJul 2026
First PostedFeb 4, 2016
Enrollment StartJul 1, 2016
Primary CompletionMay 28, 2019
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 10.4 years ago
Interventions
CUDC-907drug